Physician Views snap poll: Skyrizi bests Cosentyx – will dermatologists respond to the data?

AbbVie has fired another salvo in the increasingly competitive psoriasis market, by announcing that its product Skyrizi bettered another biologic – Novartis' Cosentyx – in a 52-week head-to-head study.

There are a few things to note here: Cosentyx has now come second-best in two head-to-head show-downs, having been beaten by Johnson & Johnson's Tremfya in a 48-week trial just over a year ago. Positive data for Skyrizi would therefore support an argument that monoclonal antibodies targeting IL-23 (as Tremfya also does) provide greater long-term efficacy over IL-17 inhibitors, such as Cosentyx.

The results could be a boon for AbbVie, which has seen Skyrizi launch strongly following its approval last year and quickly find favour with prescribers (see Physician Views Results – AbbVie's Skyrizi makes a strong early impression in psoriasis). It is primed to be one of the company's key sales growth drivers over the next decade.

To get a better idea of what impact these latest results could have on the market, we are snap-polling dermatologists based in the US and EU3 (France, Germany and the UK)…

____________

Q. Would you describe yourself as a frequent prescriber of either of the two following treatments for moderate-to-severe psoriasis?

Cosentyx (secukinumab)

Skyrizi (risankizumab)

Both agents

Neither agent

____________

Q. In patients with moderate-to-severe plaque psoriasis, Skyrizi (risankizumab) met both primary and secondary endpoints versus Novartis' Cosentyx (secukinumab) in a head-to-head Phase III study. Skyrizi showed significantly higher rates of skin clearance compared to Cosentyx, meeting the primary endpoint of superiority with at least a 90% improvement from baseline in the Psoriasis Area and Severity Index (PASI 90) at week 52. More here.

Of patients treated with Skyrizi, 87% achieved PASI 90 compared to 57% of Cosentyx-treated patients at 52 weeks (p<0.001). 

At week 16, Skyrizi also met the other primary endpoint of non-inferiority to Cosentyx with 74% of Skyrizi patients achieving PASI 90 compared to 66% of Cosentyx patients.

On a scale of 1 (not impressive) to 5 (very impressive), how do you rate these data in favour of Skyrizi?

1            2            3            4            5

____________

Q. Skyrizi patients received two (75mg) subcutaneous injections at baseline, four weeks later and every 12 weeks thereafter. Cosentyx patients received two (150mg) subcutaneous injections at baseline, weeks one, two, three and four, and then every four weeks thereafter.

In a real-world setting, does less frequent dosing for Skyrizi provide a meaningful advantage over Cosentyx?

On a scale of 1 (no advantage) to 5 (significant advantage)

1            2            3            4            5

____________

Q. Will these head-to-head study results impact your own use of Skyrizi?

Use will decline notably

Use will decline

Use will stay the same

Use will increase

Use will increase notably

____________

Q. Will these head-to-head study results impact your own use of Cosentyx?

Use will decline notably

Use will decline

Use will stay the same

Use will increase

Use will increase notably

____________

Results and related analysis will shortly be published for FirstWord Pharma PLUS subscribers to read, with the opportunity for non-FirstWord Pharma PLUS subscribers to purchase these findings. To be notified when poll results and analysis become available, please click here.

As always, FirstWord would very much like to receive your feedback and suggestions.

Note: FirstWord Physician Views are a fast-turnaround service to conduct instant polls of up to five questions with guaranteed samples that include physicians from dozens of specialties in major markets. To conduct this poll with a different audience, or an entirely different poll, contact us at info@firstwordpharma.com.

Disclaimer: FirstWord follows market research best practices in conducting its Physician Views polls.  However, Physician Views results should be considered directional and clients should use their market research resources for statistical analysis and conclusions required with very high confidence levels.

To read more Physician Views articles, click here.